Cozad Asset Management Inc. Purchases 2,153 Shares of Pfizer Inc. (NYSE:PFE)

Cozad Asset Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 6.3% in the first quarter, Holdings Channel.com reports. The fund owned 36,577 shares of the biopharmaceutical company’s stock after purchasing an additional 2,153 shares during the period. Cozad Asset Management Inc.’s holdings in Pfizer were worth $927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock worth $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Northern Trust Corp raised its position in shares of Pfizer by 7.7% in the fourth quarter. Northern Trust Corp now owns 58,382,560 shares of the biopharmaceutical company’s stock worth $1,548,889,000 after buying an additional 4,167,222 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company’s stock worth $1,045,351,000 after buying an additional 1,333,740 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Pfizer by 9.6% in the fourth quarter. Invesco Ltd. now owns 29,458,139 shares of the biopharmaceutical company’s stock worth $781,524,000 after buying an additional 2,579,455 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.1%

NYSE PFE opened at $24.30 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market capitalization of $138.13 billion, a PE ratio of 17.61, a PEG ratio of 0.88 and a beta of 0.58. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The business’s 50-day moving average is $24.34 and its 200 day moving average is $24.63.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the firm earned $0.82 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 7.08%. Pfizer’s payout ratio is presently 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Citigroup raised their price target on Pfizer from $23.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Leerink Partners lowered their price target on Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research report on Wednesday, April 30th. Morgan Stanley raised their price target on Pfizer from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 30th. Finally, HSBC lowered their price target on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.